powering innovation through collaboration

Our Collaborative Spirit

We believe that partners are essential to our future. We are dedicated to working with the world’s leading experts to solve complex challenges in our field and realize our bold vision of curing cancer using the immune system in its natural form. We are committed to innovating as a team by integrating diverse expertise and exploring new ideas.

Our Partners


Massachusetts General Hospital (MGH)
TCR2 and Dr. Marcela Maus at MGH (Boston, MA) are in a collaboration focused on characterization of TRuC™-T cells and their impact on downstream pathways.


University Hospital of Ludwig-Maximilians-University (LMU)
TCR2 and LMU (Munich, Germany) have entered into a multi-year research collaboration to broaden its TRuC™-T technology platform under the direction of Drs. Stefan Endres and Sebastian Kobold


University of Freiburg
TCR2 and Dr. Wolfgang Schamel at University of Freiburg (Freiburg, Germany) are in a collaboration focused on interrogation of TCR biology, molecular structures and signaling, which will support further development of the TRuC™-T technology platform.

MPM logo.png

MPM Capital
As a MPM portfolio company, TCR2 partners with MPM and its broad network of world-class clinicians, scientists, and entrepreneurs to sharpen and expand its thinking.

Seeking Bold Ideas

We welcome opportunities to connect with any organization with bold ideas who share our collaborative spirit.

Reach out to us at partnering@tcr2.com